Unpacking the effects of adverse regulatory events : Evidence from pharmaceutical relabeling
Year of publication: |
2021
|
---|---|
Authors: | Higgins, Matthew J. ; Yan, Xin ; Chatterjee, Chirantan |
Published in: |
Research policy : policy, management and economic studies of science, technology and innovation. - Amsterdam [u.a.] : Elsevier, ISSN 0048-7333, ZDB-ID 121149-3. - Vol. 50.2021, 1, p. 1-15
|
Subject: | Regulatory shocks | Drug safety label changes | Pharmaceutical innovation | Aggregate demand | Arzneimittel | Pharmaceuticals | Regulierung | Regulation | Pharmaindustrie | Pharmaceutical industry | Arzneimittelmarkt | Pharmaceutical market | Schätzung | Estimation | Pharmakologie | Pharmacology | Wirkungsanalyse | Impact assessment | Innovation | Produktinformation | Product information |
-
Estimating the cost of strategic entry delay in pharmaceuticals : the case of Ambien CR
Shapiro, Bradley T., (2016)
-
Chapter 12. Pharmaceutical Innovation
Scherer, F.M., (2010)
-
Market Effects of Adverse Regulatory Events : Evidence from Drug Relabeling
Higgins, Matthew J., (2018)
- More ...
-
Market Effects of Adverse Regulatory Events : Evidence from Drug Relabeling
Higgins, Matthew J., (2018)
-
Market effects of adverse regulatory events : evidence from drug relabeling
Higgins, Matthew J., (2018)
-
Unpacking the Effects of Adverse Regulatory Events : Evidence from Pharmaceutical Relabeling
Higgins, Matthew John, (2018)
- More ...